The most common grades ≥3 AEs in the Zercepac group were elevated AST (29.2%), anemia (24.6%), and elevated ALT (23.1%), while the most common grades ≥3 AEs in the reference trastuzumab group were insomnia (22.5%), fatigue (15.0%), and evaluated AST (15.0%). The gene discussed is GPT; the disease is insomnia.